Cargando…
The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020
This review fully describes the coronavirus 3CL(pro) peptidomimetic inhibitors and nonpeptidic small molecule inhibitors developed from 2010 to 2020. Specifically, the structural characteristics, binding modes and SARs of these 3CL(pro) inhibitors are expounded in detail by division into two categor...
Autores principales: | Liu, Yuzhi, Liang, Chengyuan, Xin, Liang, Ren, Xiaodong, Tian, Lei, Ju, Xingke, Li, Han, Wang, Yongbo, Zhao, Qianqian, Liu, Hong, Cao, Wenqiang, Xie, Xiaolin, Zhang, Dezhu, Wang, Yu, Jian, Yanlin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409838/ https://www.ncbi.nlm.nih.gov/pubmed/32810751 http://dx.doi.org/10.1016/j.ejmech.2020.112711 |
Ejemplares similares
-
An update review of emerging small-molecule therapeutic options for COVID-19
por: Tian, Dengke, et al.
Publicado: (2021) -
QM/QM studies for Michael reaction in coronavirus main protease (3CL(Pro))
por: Taranto, Alex G., et al.
Publicado: (2008) -
Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic
por: Liang, Chengyuan, et al.
Publicado: (2021) -
In silico screening of potential compounds from begonia genus as 3CL protease (3Cl pro) SARS-CoV-2 inhibitors
por: Maulana, Saipul, et al.
Publicado: (2023) -
Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CL(pro)
por: Ma, Ling, et al.
Publicado: (2022)